Seth Paul Lerner

Seth Paul Lerner's AcademicInfluence.com Rankings

Seth Paul Lerner

Computer Science

#7879

World Rank

#8293

Historical Rank

Informatics

#47

World Rank

#49

Historical Rank

computer-science Degrees

Seth Paul Lerner

Philosophy

#8290

World Rank

#11642

Historical Rank

Logic

#5327

World Rank

#6718

Historical Rank

philosophy Degrees

Download Badge

Computer Science
Philosophy

Seth Paul Lerner's Degrees

Doctorate Medicine Harvard University
PhD Biomedical Informatics Stanford University

Why Is Seth Paul Lerner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Seth Paul Lerner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comprehensive molecular characterization of urothelial bladder carcinoma (2014) (1748)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2017) (1446)
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. (2006) (648)
Two molecular pathways to transitional cell carcinoma of the bladder. (1994) (630)
Treatment of Non‐Metastatic Muscle‐Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (2017) (612)
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer (2018) (574)
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. (2017) (572)
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance (2014) (459)
Bladder cancer (2016) (391)
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. (2013) (378)
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. (2007) (329)
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. (2004) (302)
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. (2007) (300)
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. (2001) (291)
Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). (2018) (282)
Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. (2004) (281)
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. (2006) (278)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2018) (277)
The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. (1993) (271)
Three differentiation states risk-stratify bladder cancer into distinct subtypes (2012) (247)
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes (2014) (246)
Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy (2006) (235)
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. (2015) (224)
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. (2012) (223)
Stage specific lymph node metastasis mapping in radical cystectomy specimens. (2004) (222)
Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. (2006) (220)
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC) (2017) (215)
Prevention and management of complications following radical cystectomy for bladder cancer. (2010) (207)
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. (2011) (206)
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy (2008) (199)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. (2010) (198)
Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy (2005) (193)
Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. (2004) (192)
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. (2012) (188)
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. (2009) (187)
Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting (2016) (180)
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. (2010) (176)
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. (2017) (169)
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy (2009) (167)
Expression of estrogen receptors‐α and ‐β in bladder cancer cell lines and human bladder tumor tissue (2006) (166)
Role of chromosome 9 in human bladder cancer. (1993) (165)
Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. (2006) (165)
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. (2007) (164)
Precystectomy nomogram for prediction of advanced bladder cancer stage. (2006) (161)
Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. (2005) (159)
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. (2017) (155)
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. (2010) (153)
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial (2018) (151)
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy (2010) (147)
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. (2009) (147)
Genome-wide association study identifies multiple loci associated with bladder cancer risk. (2014) (136)
Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. (2007) (136)
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin. (2013) (130)
Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. (2003) (126)
Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. (2003) (125)
The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder (2010) (125)
Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer (1999) (122)
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. (2017) (119)
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. (2001) (119)
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. (2006) (117)
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. (2019) (116)
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling (2019) (115)
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. (2020) (110)
Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. (2006) (106)
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise (2015) (106)
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. (2006) (99)
Calcium Oxalate Deposition in Renal Cell Carcinoma Associated With Acquired Cystic Kidney Disease: A Comprehensive Study (2005) (98)
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. (2011) (97)
Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. (2002) (97)
Radical cystectomy in regionally advanced bladder cancer. (1992) (96)
The risk of dying of prostate cancer in patients with clinically localized disease. (1991) (95)
Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. (1999) (95)
Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma (2001) (94)
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. (2011) (92)
Occupational risk factors (2008) (90)
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. (2003) (90)
Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. (2005) (90)
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. (2014) (88)
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. (2009) (84)
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. (2007) (84)
Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG (2015) (82)
Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. (2009) (82)
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. (2013) (82)
E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. (2001) (80)
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. (2010) (76)
Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. (2000) (76)
p53 expression in patients with advanced urothelial cancer of the urinary bladder (2010) (74)
Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. (2003) (74)
Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials (2019) (72)
Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort (2006) (71)
Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. (2014) (71)
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. (2003) (70)
High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. (2007) (68)
Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. (2001) (67)
Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer (2009) (66)
Novel endoscopic diagnosis for bladder cancer (2015) (66)
Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. (2010) (66)
Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. (1999) (66)
Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. (2012) (65)
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome (2007) (65)
Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. (2008) (64)
Lymphadenectomy for bladder cancer at the time of radical cystectomy. (2013) (64)
Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer (2019) (64)
Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. (2014) (62)
A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? (2010) (62)
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710 (2014) (61)
Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer (2008) (60)
Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy (2013) (60)
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. (2017) (60)
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. (2020) (59)
Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. (2007) (58)
p53 predictive value for pT1-2 N0 disease at radical cystectomy. (2009) (58)
Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. (2003) (57)
Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder (2001) (57)
Cancer specific outcomes in patients with pT0 disease following radical cystectomy. (2006) (56)
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. (2010) (55)
Positive association of collagen type I with non-muscle invasive bladder cancer progression (2016) (52)
Application of new technology in bladder cancer diagnosis and treatment (2009) (51)
Centrosomal abnormality is common in and a potential biomarker for bladder cancer (2003) (49)
Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I. (2011) (47)
Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. (2019) (46)
Adenovirus-mediated suicide gene therapy for experimental bladder cancer. (1997) (46)
Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review (2012) (46)
A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer (2011) (46)
Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study (2006) (46)
Raloxifene Inhibits Growth of RT4 Urothelial Carcinoma Cells via Estrogen Receptor-Dependent Induction of Apoptosis and Inhibition of Proliferation (2012) (45)
Neutrophil‐to‐lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710 (2016) (45)
Dietary carotenoids and genetic instability modify bladder cancer risk. (2004) (44)
Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer (2017) (44)
Polymorphisms in XPD Exons 10 and 23 and Bladder Cancer Risk (2005) (44)
Urothelial carcinoma of the prostate. (2007) (42)
Retinoids in the chemoprevention of bladder cancer (1998) (42)
Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1 (2004) (41)
Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. (2013) (41)
Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). (2020) (40)
Infection stones. (1989) (40)
Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior (2017) (40)
Renal cell carcinoma with an infrarenal vena caval tumor thrombus. (1999) (39)
Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen. (2013) (39)
Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival (2016) (37)
Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. (1999) (36)
Examining Sexual Dysfunction in Non-Muscle-Invasive Bladder Cancer: Results of Cross-Sectional Mixed-Methods Research (2014) (36)
Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. (2019) (36)
Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. (2005) (35)
Case-Control Analysis of Dietary Folate and Risk of Bladder Cancer (2005) (35)
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. (2017) (34)
Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. (2006) (33)
Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (2016) (33)
Dasatinib Is Preclinically Active against Src-Overexpressing Human Transitional Cell Carcinoma of the Urothelium with Activated Src Signaling (2010) (32)
Bladder cancer detection, treatment and outcomes: opportunities and challenges. (2010) (32)
Bladder cancer clinical trials. (2005) (32)
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy (2010) (32)
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) (2021) (31)
The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. (2003) (30)
Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer. (2008) (29)
Textbook of bladder cancer (2015) (29)
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis (2018) (29)
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. (2007) (29)
Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. (2003) (29)
Urinary levels of urokinase‐type plasminogen activator and its receptor in the detection of bladder carcinoma (2002) (29)
Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. (2017) (29)
Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naïve High-grade Non-muscle-invasive Bladder Cancer. (2018) (28)
Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. (1997) (28)
Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. (2001) (28)
Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. (2011) (28)
735: Differential Expression of Estrogen Receptor α and β in Bladder Cancer Cell Lines and Human Bladder Tumor Tissue (2004) (27)
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. (2014) (26)
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. (2019) (25)
Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival (2007) (25)
Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. (2020) (25)
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. (2020) (25)
Giant bilateral renal angiomyolipomas associated with tuberous sclerosis. (2001) (25)
Granulocyte colony-stimulating factor receptor signals for beta1-integrin expression and adhesion in bladder cancer. (2004) (24)
Review: Use of nomograms for predictions of outcome in patients with advanced bladder cancer (2009) (23)
Molecular Subtypes of Non-muscle Invasive Bladder Cancer. (2016) (22)
Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined node-negative urothelial bladder cancer (UBC). (2009) (22)
Management of Metastatic and Invasive Bladder Cancer (2012) (22)
Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. (2000) (22)
Educational Opportunities in Bladder Cancer: Increasing Cystoscopic Adherence and the Availability of Smoking-Cessation Programs (2014) (22)
Treatment of staghorn calculi with extracorporeal shock-wave lithotripsy and percutaneous nephrolithotomy. (1991) (20)
The role of surgery in the management of pediatric pelvic rhabdomyosarcoma. (1995) (20)
Significance of lymphovascular invasion in organ‐confined, node‐negative urothelial cancer of the bladder: data from the prospective p53‐MVAC trial (2015) (20)
Perioperative chemotherapy for upper tract urothelial cancer (2012) (20)
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report (2021) (19)
Novel agents for muscle‐invasive and advanced urothelial cancer (2008) (19)
Positive margins after radical prostatectomy: implications for failure and role of adjuvant treatment. (2013) (19)
Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. (2020) (18)
Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. (2015) (18)
Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. (2003) (17)
EVIDENCE-BASED GENDER RELATED OUTCOMES AFTER RADICAL CYSTECTOMY: RESULTS OF A LARGE MULTICENTER STUDY (2009) (17)
Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. (2018) (17)
Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy. (2015) (17)
Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts (2019) (17)
External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. (2011) (17)
Dietary patterns and risk of recurrence and progression in non‐muscle‐invasive bladder cancer (2018) (17)
Innovations in radical cystectomy and pelvic lymph node dissection. (2012) (17)
Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter. (2000) (17)
Metastatic transitional cell carcinoma of the urinary bladder to the shoulder girdle. (2002) (16)
The Cancer Genome Atlas Project in Bladder Cancer. (2018) (15)
In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. (2000) (15)
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC 14 A 1 , a urea transporter gene on chromosome 18 q 12 . 3 (2011) (15)
Perioperative chemotherapy in locally advanced bladder cancer (2003) (15)
Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. (2009) (15)
Conservative management of spontaneous rupture of Kock orthotopic ileal reservoir. (1997) (14)
Variables affecting long-term maintenance of renal function following ileal based urinary diversion. (2012) (14)
Renal cell carcinoma and situs inversus viscerum. (1998) (14)
Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer. (2016) (14)
Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage (2014) (14)
Bropirimine immunotherapy of upper urinary tract carcinoma in situ. (1996) (14)
Postradical orchiectomy hemorrhage: should an alteration in staging strategy for testicular cancer be considered? (1995) (14)
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. (2016) (14)
Adenocarcinoma following urinary diversion. (2012) (13)
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. (2021) (13)
What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy? (2019) (13)
Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine (2009) (13)
Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups (2022) (13)
New imaging techniques for nonmuscle invasive bladder cancer (2014) (12)
Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. (2001) (12)
Adjuvant chemotherapy for bladder cancer does not alter cancer‐specific survival after cystectomy in a matched case‐control study (2008) (12)
Critical analysis of contemporary clinical research in muscle‐invasive and metastatic urothelial cancer (2013) (12)
New trends in the surgical management of invasive bladder cancer. (2015) (12)
The use and abuse of data: nomograms and talking to patients about clinical medicine. (2007) (11)
Chemoprevention of bladder cancer (2006) (11)
Molecular Landscape of Non-Muscle Invasive Bladder Cancer. (2017) (11)
Strategies to prevent progression of high-risk bladder cancer at initial diagnosis (2012) (11)
S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer. (2017) (10)
INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients. (2021) (10)
The Role and Extent of Pelvic Lymphadenectomy in the Management of Patients with Invasive Urothelial Carcinoma (2009) (10)
Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma (2008) (10)
MP77-08 MITOGEL: OPTIMIZING DRUG DELIVERY TO THE UPPER URINARY TRACT—A PRECLINICAL EVALUATION (2014) (10)
A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. (2012) (10)
Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study (2016) (10)
Bacillus Calmette-Guérin Manufacturing and SWOG S1602 Intergroup Clinical Trial. (2017) (10)
Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. (2017) (10)
264: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Carcinoma in Situ of the Urinary Bladder (2004) (10)
NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer. (2014) (10)
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. (2019) (9)
263: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Stage TA/T1 Urothelial Cancer in the Urinary Bladder (2004) (9)
Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines (2016) (9)
BCAN Think Tank session 3: Prevention of bladder cancer. (2010) (9)
Bladder cancer: Diagnosis and clinical management (2015) (9)
Targeted therapies for metastatic bladder cancer. (2015) (9)
178 Pre-clinical and clinical translation of a tissue engineered neo–urinary conduit using adipose derived smooth muscle cells for urinary reconstruction (2014) (9)
LYMPHOVASCULAR INVASION IS A POWERFUL PREDICTOR OF CLINICAL OUTCOMES IN NODE-NEGATIVE RADICAL CYSTECTOMY PATIENTS: AN INTERNATIONAL EXTERNAL VALIDATION STUDY (2009) (9)
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ‐confined, node‐negative urothelial carcinoma of the bladder (2015) (8)
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations. (2020) (8)
Innovations in endoscopic imaging for bladder cancer. (2009) (8)
Combining surgery and chemotherapy for invasive bladder cancer: current and future directions (2006) (8)
Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). (2014) (8)
Bacille-Calmette-Guerin non-responders: how to manage (2015) (8)
COMBINATION OF CELL CYCLE REGULATING BIO-MARKERS IMPROVES PROGNOSIS IN PATIENTS WITH ORGAN CONFINED UROTHELIAL CANCER AT RADICAL CYSTECTOMY (2008) (8)
FLUORESCENCE AND WHITE LIGHT CYSTOSCOPY FOR DETECTING CARCINOMA IN SITU OF THE BLADDER (2008) (8)
MP65-02 A PHASE III SURGICAL TRIAL TO EVALUATE THE BENEFIT OF A STANDARD VERSUS AN EXTENDED PELVIC LYMPHADENECTOMY PERFORMED AT TIME OF RADICAL CYSTECTOMY FOR MUSCLE INVASIVE UROTHELIAL CANCER: SWOG S1011 (NCT #01224665) (2015) (8)
Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence. (2014) (7)
Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult. (2005) (7)
INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806. (2020) (7)
Risk‐adapted use of intravesical chemotherapy (2008) (7)
Current Status of Gene Therapy for Prostate and Bladder Cancer (1997) (7)
Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer (2017) (7)
1666 SWOG S0353 PHASE II TRIAL OF INTRAVESICAL GEMCITABINE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER WHO RECURRED FOLLOWING AT LEAST TWO PRIOR COURSES OF BCG (2012) (7)
The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. (2014) (6)
Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa). (2014) (6)
Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological Variants (2018) (6)
The preclinical activity of lenalidomide in indolent urothelial carcinoma. (2014) (6)
The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. (2015) (6)
Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop (2021) (6)
Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma (2021) (6)
RISK ASSESSMENT OF T1 TRANSITIONAL CELL CARCINOMA OF THE BLADDER USING P53 IMMUNOHISTOCHEMISTRY AND PATHOLOGIC SUBSTAGING (1999) (6)
Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer. (2021) (6)
Prostatic transitional cell carcinoma: pathologic features and clinical management (2007) (6)
LBA-16 NEPHRON-SPARING MANAGEMENT OF LOW GRADE (LG) UTUC WITH UGN-101 (MITOMYCIN GEL) FOR INSTILLATION: THE OLYMPUS TRIAL EXPERIENCE (2019) (6)
832: Optimized Intravesical Mitomycin C Treatment for Superficial Bladder Cancer: Long-Term Follow-Up (2006) (6)
Sunitinib malate is active and synergistic with cisplatin against human urothelial carcinoma in a preclinical model (2007) (6)
Diagnostic and Prognostic Markers in Bladder Cancer (2016) (6)
Alternatives to cytology in the management of non-muscle invasive bladder cancer (2004) (5)
Precision Molecular Pathology of Bladder Cancer (2018) (5)
1374: The Sensitivity of Transurethral Biopsy for Detecting Prostatic Involvement by Transitional Cell Carcinoma in Patients Undergoing Radical Cystoprostatectomy (2005) (5)
Editorial comment on: Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. (2007) (5)
Update on The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. (2015) (5)
Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. (2017) (5)
Urinary Bladder, Ureter, and Urethra (2009) (5)
Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas. (2017) (5)
DNA methylation patterns in bladder tumors of African-American patients point to distinct alterations in xenobiotic metabolism. (2019) (5)
Editorial (2015) (5)
913: Results of a Randomized Chemoprevention Trial with Fenretinide in Non-Muscle Invasive Bladder Cancer (2005) (5)
Racial/ethnic differences in upper-tract urothelial cancer. (2011) (5)
Treatment of high-risk, non-muscle-invasive bladder cancer (2006) (5)
Bladder Cancer Screening Program for a Petrochemical Cohort with Potential Exposure to Beta-napthylamine (2003) (5)
Treatment and management of bladder cancer (2008) (4)
Genomic Assessment of Muscle-Invasive Bladder Cancer: Insights from the Cancer Genome Atlas (TCGA) Project (2018) (4)
Rebuilding the lower urinary tract after cystectomy: a roadmap for patient selection and counseling. (2001) (4)
Cancers of the Urinary Tract (1998) (4)
The loss of expression of transforming growth factor-beta receptors correlates with the histopathologic tumor grade in bladder transitional cell carcinoma patients. (1999) (4)
Lymphadenectomy for Bladder Cancer (1995) (4)
Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695). (2020) (4)
PD66-01 IMMEDIATE POST TURB INTRAVESICAL GEMCITABINE: A COST COMPARISON BASED ON SWOG S0337 (2018) (4)
Transurethral biopsy of the prostatic urethra is associated with final apical margin status at radical cystoprostatectomy (2016) (4)
PD17-06 RANDOMIZED PHASE II TRIAL OF INTRAVESICAL ADENOVIRAL MEDIATED INTERFERON-α GENE THERAPY WITH THE EXCIPIENT SYN3 (RAD-IFNα/SYN3) IN PATIENTS WITH BCG REFRACTORY OR RELAPSING HIGH GRADE (HG) NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) (2015) (4)
LBA25 NON-SURGICAL MANAGEMENT OF LOW GRADE UPPER TRACT UROTHELIAL CANCER: AN INTERIM ANALYSIS OF THE INTERNATIONAL MULTICENTER OLYMPUS TRIAL (NCT02793128) (2018) (4)
Effects of the histone deacetylase inhibitor FK228 in improving adenoviral mediated gene expression and suicide gene therapy inhumanTCC-sup bladder cancer (2004) (4)
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations. (2020) (4)
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial (2021) (3)
Weighted Gleason Grade Group (WGGG): A new prostate cancer biopsy reporting system with prognostic potential. (2019) (3)
Comprehensive genomic characterization of upper tract urothelial carcinoma (UTUC). (2017) (3)
Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment (2020) (3)
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. (2022) (3)
Phase II trial of tamoxifen for progressive advanced urothelial carcinoma following prior chemotherapy. (2012) (3)
Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy (2019) (3)
1604 EVALUATION OF PREOPERATIVE SERUM CA19-9 AS PREDICTOR OF ADVERSE PATHOLOGIC FEATURES AND CLINICAL OUTCOME IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER UNDERGOING RADICAL CYSTECTOMY AND EXTENDED LYMPH NODE DISSECTION (2011) (3)
A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma. (2013) (3)
1518: Comparing Long-Term Health Related Quality of Life Challenges in Patients with Ileal Conduit Vs Continent Cutaneous Diversion vs Orthotopic Neobladder (2007) (3)
Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. (2008) (3)
SIU–ICUD consultation on bladder cancer: basic science (2018) (3)
Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer. (2021) (3)
Thermo reversible hydrogel based delivery of mitomycin C for treatment of upper tract urothelial carcinoma (UTUC). (2017) (3)
LBA6 FINAL RESULTS OF A PHASE 1 CLINICAL TRIAL EVALUATING THE USE OF A TISSUE ENGINEERED NEO-URINARY CONDUIT USING ADIPOSE DERIVED SMOOTH MUSCLE CELLS FOR URINARY RECONSTRUCTION (2018) (3)
The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer. (2021) (3)
Treatment of non-muscle-invasive bladder cancer (2012) (3)
Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]. (2015) (2)
Abstract 2969: Progress in The Cancer Genome Atlas bladder cancer project (2015) (2)
The case for salvage cystectomy after pelvic radiation. (2016) (2)
Comprehensive radiogenomics analysis of qualitative and quantitative features of cross-sectional imaging in the TCGA project in MIBC. (2019) (2)
13 OUTCOMES OF PATIENTS WITH CLINICAL T1 GRADE 3 BLADDER UROTHELIAL CELL CARCINOMA TREATED WITH RADICAL CYSTECTOMY (2007) (2)
Novel therapeutic approach for bladder cancer: Synergistic effects with combined radiation and suicide gene therapy using a chimeric adenovirus vector (2004) (2)
485 MULTI-INSTITUTIONAL QUALITY OF CARE INITIATIVE FOR NON-METASTATIC MUSCLE-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER: PHASE 1 (2011) (2)
Authors' Disclosures of Potential Conflicts of Interest Theauthorsindicatednopotentialconflictsofinterest. (2005) (2)
Outreach and Influence of Surgical Societies’ Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemic—An Anonymized International Urologic Expert Inquiry (2020) (2)
Utility of lymphadenectomy in bladder cancer: where do we stand? (2020) (2)
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinoma (TCC). (2016) (2)
CIS of the Bladder: Significance and Implications for Therapy (2019) (2)
Accuracy of the Extent of Bladder Cancer Nodal Metastases Found at Pelvic Lymphadenectomy at the Time of Cystectomy: Relation to Primary Tumor Stage (2010) (2)
Comparison of the 5637 human urothelial cancer cell line with a second-generation 5637 cell line for cancer therapy (2008) (2)
1231: Delay in Radical Cystectomy Over 12 Weeks is Not Associated with Adverse Outcome: Results from the Bladder Cancer Research Consortium (2006) (2)
A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial. (2011) (2)
Erratum to "Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder" [Eur Urol Focus 2018;4:907-915]. (2019) (2)
Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence. (2013) (2)
COST IMPLICATION OF USING UROVYSION IN SURVEILLANCE CARE FOR NON-INVASIVE BLADDER CANCER (2009) (2)
RESULTS OF A PHASE II/III TRIAL OF CELECOXIB TO PREVENT RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER (2009) (2)
Efficacy of selective estrogen receptor modulators (SERMs) in a murine xenograft model bearing human bladder cancer (2005) (2)
Neoadjuvant chemotherapy for bladder cancer. (2007) (2)
Prevention and management of complications following radical cystectomy for bladder cancer (2010) (2)
Neoadjuvant chemotherapy preceding cystectomy for bladder cancer (2008) (2)
Therapeutic Effect on Bladder Cancer with a Conditionally Replicating Oncolytic Virus Derived from Type II Herpes Simplex Virus (2015) (2)
VARIABILITY IN SURGICAL QUALITY IN A RANDOMIZED CLINICAL TRIAL OF ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL CYSTECTOMY AND PELVIC LYMPHADENECTOMY (2009) (2)
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up. (2022) (2)
Radical cystectomy: Techniques and outcomes (2015) (2)
1656: Transurethral Resection Biopsy of the Prostatic and Apical Margin Status at Radical Cystoprostatectomy (2007) (2)
Improved Diagnostic Techniques (2015) (2)
POD-05.06 Optical Coherence Tomography (OCT) as an Adjunct to Conventional Cystoscopy and Pathology for Non-Invasive Endoscopic Staging of Bladder Tumors (2011) (2)
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. (2023) (1)
Phase III PreventionTrial of Fenretinide in Patients with Resected Non ^ Muscle-Invasive Bladder Cancer (2007) (1)
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. (2022) (1)
787 The Cancer Genome Atlas (TCGA) project analysis of micro-RNA and gene expression subtypes of high-grade, muscle-invasive urothelial carcinoma (2016) (1)
Prerandomization factors and utilization of neoadjuvant chemotherapy in a clinical trial of extended versus standard pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer. (2014) (1)
Abstract 3771: Mitochondrial metabolism and racial disparity of bladder cancer (2022) (1)
Editorial Comment. (2016) (1)
A Festschrift in Honor of Edward M. Messing, MD, FACS (2018) (1)
LBA-19 PHASE II TRIAL OF ESTROGEN RECEPTOR TARGETED TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER WITH TAMOXIFEN (2019) (1)
721: Raloxifene, a Selective Estrogen Receptor Modulator, Induces Apoptosis in Bladder Cancer Cell Lines (2004) (1)
MULTIPLE BIO-MARKERS FOR THE PREDICTION OF BLADDER CANCER RECURRENCE AND MORTALITY (2008) (1)
COMPREHENSIVE GENOMIC CHARACTERIZATION OF UPPER TRACT UROTHELIAL CARCINOMA (UTUC): MP71‐01 (2017) (1)
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press. (2020) (1)
COMPETING RISKS NOMOGRAM PREDICTING THE PROBABILITY OF BLADDER CANCER RECURRENCE AFTER CYSTECTOMY CAN RELIABLY DISTINGUISH BETWEEN TUMOURS DESTINED TO RECUR AND PATIENTS WHO MAY DIE OF OTHER CAUSES BEFORE RECURRENCE (2006) (1)
1715 CELL CYCLE REGULATORY PROTEIN ALTERATIONS IN A PROSPECTIVE STUDY OF PATIENTS WITH ORGAN-CONFINED BLADDER CANCER FOLLOWING RADICAL CYSTECTOMY (2010) (1)
301: Pelvic Lymph Nodes as a Prognostic Factor in Patients Undergoing Radical Cystectomy for Invasive Transitional Cell Carcinoma: A Multicenter Study (2004) (1)
194: Head-to-Head Comparison of Histologic and Functional Properties of Rat Bladders Augmented with a Novel Blood Vessel Matrix Vs Small Intestine Submucosa (2007) (1)
MP48-18 FEMALE PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA: PRIMARY CHEMOABLATION AND DURABILITY OF RESPONSE IN A SUBGROUP ANALYSIS FROM THE OLYMPUS TRIAL (2021) (1)
Novel Thermo-Sensitive Hydrogel Therapy for Low-Grade Upper Tract Urothelial Carcinoma. (2021) (1)
Systematic Review and Meta-Analysis of Response Rates in BCG-unresponsive Non–Muscle-Invasive Bladder Cancer: a Consensus Statement From the International Bladder Cancer Group (2022) (1)
Bladder Cancer Today (2008) (1)
Seminar articlesEditorial comment (2004) (1)
VAX014 for instillation in subjects with nonmuscle-invasive bladder cancer. (2022) (1)
A PHASE III BLINDED STUDY OF IMMEDIATE POST‐TURBT INSTILLATION OF GEMCITABINE VERSUS SALINE IN PATIENTS WITH NEWLY DIAGNOSED OR OCCASIONALLY RECURRING GRADE I/II NON‐MUSCLE INVASIVE BLADDER CANCER: SWOG S0337: PNFLBA‐10 (2017) (1)
MP60-12 MULTI-INSTITUTIONAL QUALITY CARE INITIATIVE TO IMPROVE THE CARE OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER (2014) (1)
591: Efficacy of Selective Estrogen Receptor Modulators (SERMS) in a Murine Xenograft Model Bearing Human Bladder Cancer (2005) (1)
Re: Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. (2000) (1)
Robust Risk Stratification Model Predicts Local-Regional Recurrence After Radical Cystectomy in Different Patient Cohorts (2013) (1)
ONE-YEAR OUTCOME OF BLADDER AUGMENTATION WITH A NOVEL BIODEGRADABLE MATRIX IN A PORCINE MODEL (2008) (1)
Testing New Ways to Measure How Patients Rate Quality of Life (2020) (1)
199 CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CLINICAL CARCINOMA IN SITU ONLY TREATED WITH RADICAL CYSTECTOMY: AN INTERNATIONAL STUDY OF 243 PATIENTS (2010) (1)
Validating a local failure risk stratification for use in a prospective study of adjuvant radiation in bladder cancer. (2015) (1)
1252: Impact of Concomitant Carcinoma in situ on Clinical Outcomes after Radical Cystectomy (2006) (1)
Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project. (2014) (1)
Fast Facts: Bladder Cancer (2018) (1)
Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) (2021) (1)
576: Patient Randomization Factors in the P53 Targeted Therapy Trial in Bladder Cancer (SWOG 4B951) (2007) (1)
1511: Outcomes of Patients with Clinical T1 Grade 3 Bladder Urothelial Cell Bladder Carcinoma Treated with Radical Cystectomy (2007) (1)
Phase III bladder cancer chemoprevention trial with fenretinide. (2006) (1)
DISCREPANCY BETWEEN CLINICAL AND PATHOLOGICAL STAGE: IMPACT ON PROGNOSIS FOLLOWING RADICAL CYSTECTOMY (2006) (1)
1230: Evidence Based Gender Related Outcomes after Radical Cystectomy (2006) (1)
Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project. (2016) (1)
1378: Are Patients who are PT0 Following Radical Cystectomy Cured of Bladder Cancer? Results from the Bladder Cancer Research Consortium (BCRC) (2005) (1)
Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) (2021) (1)
302: Lymphovascular Invasion Independently Predicts Increased Risk of Distant Recurrence and Decreased Overall Survival in Patients with Transitional Cell Carcinoma (TCC) (2004) (1)
1116: A Prognostic Tool to Identify Patients at High Risk of Relapse at 2, 5 and 8 Years after Cystectomy for Transitional Cell Carcinoma (TCC) of the Urinary Bladder: Nomogram Development and Internal Validation (2005) (1)
799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations (2020) (1)
Non-Coding RNA modulate molecular subtype biology in muscle invasive bladder cancer (MIBC) and are independently associated with survival (2017) (0)
Educational Opportunities in Bladder Cancer: Increasing Cystoscopic Adherence and the Availability of Smoking-Cessation Programs (2014) (0)
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling (2019) (0)
Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer. (2020) (0)
Urinary tract reconstruction--the expanding surgical armamentarium. (1996) (0)
Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation for Bladder Cancer (2016) (0)
Overview of SUO Winter 2008 proceedings. (2010) (0)
LYMPHOVASCULAR INVASION (LVI) IS INDEPENDENTLY ASSOCIATED WITH BLADDER CANCER RECURRENCE AND SURVIVAL IN PATIENTS WITH T1 AND NEGATIVE LYMPH NODES AT RADICAL CYSTECTOMY (2008) (0)
Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence. (2011) (0)
313 ADJUVANT CHEMOTHERAPY FOR UROTHELIAL CARCINOMA OF THE URINARY BLADDER (2010) (0)
Clinical Trials in Bladder and Upper Tract Cancer – Bladder Cancer Disease States (2021) (0)
A CONDITIONAL NOMOGRAM FOR PREDICTION OF EARLY RECURRENCE OF BLADDER CANCER AFTER RADICAL CYSTECTOMY (2008) (0)
A phase 1, open-label trial to evaluate feasibility and safety of intramural injection of belzupacap sarotalocan (AU-011) in non-muscle–invasive bladder cancer (NMIBC). (2023) (0)
902 Transurethral biopsy of the prostatic urethra frequently detects carcinoma in-situ and invasive urothelial carcinoma arising from the prostatic urethra and ducts/acini (2014) (0)
Extent of neutrophil (NTP) infiltration in benign lymph nodes (LNs) to predict survival in patients with muscle-invasive bladder cancer (MIBC). (2013) (0)
Highlights of the 2010 SUO Annual Meeting. (2011) (0)
MP65-05 TRANSURETHRAL BIOPSY OF THE PROSTATIC URETHRA FREQUENTLY DETECTS CARCINOMA IN-SITU AND INVASIVE UROTHELIAL CARCINOMA ARISING FROM THE PROSTATIC URETHRA AND DUCTS/ACINI (2014) (0)
Editorial comment. (2010) (0)
1773 PREDICTION OF RECURRENCE AND PROGRESSION IN THE CONTEXT OF THE CHARLSON COMORBIDITY INDEX IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (2013) (0)
Abstract 9: Metabolic profiling of bladder cancer cell lines reveals molecular alterations involved in methylation and novel epigenetic phenotype (2016) (0)
THERAPEUTIC EFFECT ON BLADDER CANCER WITH A CONDITIONALLY REPLICATING ONCOLYTIC VIRUS DERIVED FROM HERPES SIMPLEX VIRUS TYPE II (2008) (0)
316: Risk Factors for Distant vs. Local Recurrence in Patients Undergoing Radical Cystectomy for Transitional Cell Cancer (2004) (0)
Comprar Treatment and Management of Bladder Cancer | Cora Sternberg | 9780415462174 | Informa Healthcare (2008) (0)
130Prognostic utility of the 1997 TNM bladder cancer substaging classification system for PT2 and PT3 disease: Results from the bladder cancer research consortium (BCRC) (2005) (0)
New Sister Journal Kidney Cancer (2017) (0)
Abstract 3922: Proteomic profiling of muscle invasive bladder cancer (2022) (0)
Abstract 5274: Multi-omics integration analysis robustly predicts high grade patient survival and identified altered fatty acid metabolism in high grade bladder cancer (2019) (0)
Concerning “ Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy ” (0)
885: Combination Treatment of Fiber-Modified Adenovirus Based HSV-1 Thymidine Kinase/Ganciclovir Gene Therapy with Docetaxel for Bladder Cancer (2007) (0)
Residual pathologic stage at radical cystectomy and risk stratification of patients with pT2N0 bladder cancer. (2009) (0)
Immunohistochemical Analysis of p16 in Bladder Cancer (2000) (0)
1032 VALIDATION OF RESIDUAL PATHOLOGIC STAGE AT RADICAL CYSTECTOMY AS A PROGNOSTIC FACTOR IN PATIENTS WITH CT2N0 BLADDER CANCER (2010) (0)
Prediction of survival in patients with muscle-invasive bladder cancer (MIBC) by neutrophil (NTP) infiltration in benign lymph nodes (LNs). (2013) (0)
PCN113 HEALTH RELATED QUALITY OF LIFE, FEAR OF RECURRENCE, IMPACT OF EVENTS, ILLNESS INTRUSIVENESS AND PSYHOLOGICAL DISTRESS IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS (2010) (0)
Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model (2022) (0)
1779 BLADDER BIOPSY AT 3 MONTHS POST- BACILLUS CALMETTE-GUERIN (BCG) INDUCTION FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) IS NOT CORRELATED WITH ONCOLOGICAL OUTCOMES (2013) (0)
Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011). (2022) (0)
Abstract 2394: Racial disparity in bladder cancer and identification of altered metabolism in African American compared to European American bladder cancer (2018) (0)
Clinical Trial Update The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer (2015) (0)
PD18-07 PRIMARY CHEMOABLATION FOR THE TREATMENT OF LOW GRADE UPPER TRACT UROTHELIAL CARCINOMA: THE OLYMPUS TRIAL (2020) (0)
856: Dietary Carotenoids and Genetic Instability Modify Bladder Cancer Risk (2005) (0)
Associations between genetic pathways and radiomic metrics in muscle-invasive bladder cancer (2019) (0)
1831 THE PROGNOSTIC ABILITY OF VARIOUS NODAL CODING SCHEMES IN BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY: RESULTS FROM THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS DATABASE (2010) (0)
For how long after flexible cystoscopy do artifactual cytological changes of urine persist? (2005) (0)
983: Bladder Cancer Predisposition: A Pathway-Based Approach to DNA Repair and Cell Cycle Control Genes (2006) (0)
Surgical management of high-risk upper tract urothelial carcinoma (2015) (0)
CEP-11981, a small molecule inhibitor of multiple angiogenic targets, in a preclinical system of urothelial carcinoma (UC). (2013) (0)
1029 CHANGE IN PATHOLOGICAL N-STAGE ASSOCIATED WITH EXTENDED LYMPH NODE DISSECTION AND RADICAL CYSTECTOMY IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER (2010) (0)
Abstract 987: Comprehensive characterization of urothelial bladder cancer: a TCGA Project update (2014) (0)
MP41-17 DOES NEOADJUVANT CHEMOTHERAPY AFFECT THE RATE OF COMPLICATIONS AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER? (2021) (0)
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937. (2023) (0)
Abstract 5470: Blocking wound-induced tumor repopulation between chemotherapy cycles as a novel approach to abrogate chemoresistance (2015) (0)
Abstract 2239: Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study (2018) (0)
946: A Chimeric Adenovirus Vector Enhaces Suicide Gene Therapy for Bladder Cancer (2004) (0)
Renal cell carcinoma extending into the retrohepatic inferior vena cava. (2014) (0)
MP32-02 ASSOCIATIONS BETWEEN GENETIC PATHWAYS AND RADIOMIC METRICS IN MUSCLE-INVASIVE BLADDER CANCER (2019) (0)
784: Therapeutic Effects of Combination Radiation and Suicide Gene Therapy Using a Chimeric Adenovirus Vector for Bladder Cancer (2005) (0)
Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer (BC) analysis. (2014) (0)
1263: Competing Risks Nomogram Predicting the Probability of Bladder Cancer Recurrence after Cystectomy can Reliably Distinguish between those Destined to Recur and those who May Die of Other Causes before Recurrence (2006) (0)
Evolving the surgical approach for bladder cancer — robotic versus open radical cystectomy (2022) (0)
Editorial: Urinary Tract Reconstruction--The Expanding Surgical Armamentarium (1996) (0)
1898 CLINICAL CARCINOMA IN SITU ONLY DISEASE: OUTCOMES OF PATIENTS TREATED WITH RADICAL CYSTECTOMY (2011) (0)
Clinical Cancer esearch cer Therapy : Clinical Effectiveness of Off-Protocol Adjuvant Chemotherapy for R ients with Urothelial Carcinoma of the Urinary Bladder (2010) (0)
1249: Internal Validation of a Competing-Risks Survival Nomogram for Patients Treated with Cystectomy for Bladder Cancer (2006) (0)
771: Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival (2005) (0)
State of the Art : Novel Kidney Cancer Genes : PBRM 1 / Histone Modifiers (2015) (0)
Therapeutic Effects of Combination Radiation and Suicide Gene Therapy Using a Chimeric Adenovirus Vector for Bladder Cancer (2005) (0)
VETERANS WITH NONMUSCLE-INVASIVE BLADDER CANCER REPORT WORSE HRQOL THAN PRIVATE PATIENTS (2009) (0)
Reply by the authors. (2014) (0)
1711 ANALYSIS OF PATIENTS WITH BLADDER CANCER INVOLVING LYMPH NODES ABOVE THE COMMON ILIAC BIFURCATION: IS CURE POSSIBLE WITH EXTENDED LYMPHADENECTOMY? (2010) (0)
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter (2022) (0)
Potential Role for Targeted Therapy in Muscle-Invasive Bladder Cancer from the Cancer Genome (2015) (0)
1027 A POPULATION-BASED COMPETING-RISKS ANALYSIS OF THE SURVIVAL OF PATIENTS TREATED WITH RADICAL CYSTECTOMY FOR BLADDER CANCER (2010) (0)
THE EFFECT OF COMPETING MORTALITY ON THE RISK OF BLADDER-CANCER RECURRENCE AND BLADDER CANCER SPECIFIC SURVIVAL (2006) (0)
Abstract 1928: Reporter construct for functional and real-time evaluation of cytokeratin 14+ bladder cancer stem cells (2014) (0)
Genetic aspects of bladder cancer progression (1991) (0)
Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy. (2010) (0)
MP-2.08: Anti-tumor Effect on Bladder Cancer with Conditionally Replicating Oncolytic Viruses Derived from Herpes Simplex Viruses (2008) (0)
Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy (2017) (0)
The preclinical anti-angiogenic and pro-apoptotic activity of lenalidomide in urothelial carcinoma (UC). (2013) (0)
845. The Loss Expression of Coxsackie and Adenovirus Receptor Enhances the Feature of Aggressive Bladder Cancer (2006) (0)
Abstract 894: Genetic variations in the angiogenesis pathway modulate clinical outcomes of bladder cancer (2010) (0)
Advances in diagnosis and therapy of transitional cell carcinoma of the bladder. (2006) (0)
Introduction to the special section on the ethics of marker tumors in clinical investigation (2002) (0)
Seminar article Bladder cancer clinical trials (2005) (0)
Editorial: Testis Cancer--Progress in Risk Assessment for Occult Retroperitoneal Lymph Node Metastases (1996) (0)
286. Therapeutic Approach Using External Radiation and Suicide Gene Therapy Transduced by Chimeric Adenovirus Vector for Bladder Cancer (2005) (0)
Genomic Profiling of Urothelial Carcinoma in Situ of the Bladder (2023) (0)
Integrated comprehensive genomic characterization of upper tract urothelial carcinoma (UTUC) (2017) (0)
1825 CLINICAL OUTCOME IN PATIENTS WITH PT4 UROTHELIAL CARCINOMA AT RADICAL CYSTECTOMY (2010) (0)
635 ILLNESS INTRUSIVENESS RATING SCALE AND IMPACT OF EVENTS SCALE AS QUALITY OF CARE INSTRUMENTS IN BLADDER CANCER (2011) (0)
Bladder cancer: Always consider extravesical sites when BCG fails (2014) (0)
Radical Cystectomy (2021) (0)
1382: Bladder Cancer-Specific Survival Following Radical Cystectomy for Primary Non-Transitional Cell Carcinoma (Non-TCC) of the Bladder: Results from the Bladder Cancer Research Consortium (BCRC) (2005) (0)
Re: Identification of Differential Tumor Subtypes of T1 Bladder Cancer (2021) (0)
Reply by Authors. (2022) (0)
Adult UrologyOncology: Adrenal/Renal/Upper Tract/BladderEditorial Comment (2006) (0)
CLINICAL OUTCOMES AND IMPACT OF TREATMENT ON RENAL FUNCTION FOR PATIENTS WITH SECOND PRIMARY UROTHELIAL CANCERS OF THE UPPER TRACT FOLLOWING RADICAL CYSTECTOMY: MP78‐18 (2017) (0)
Editorial comment. (2010) (0)
Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC). (2012) (0)
Adjuvant infigratinib as targeted therapy for patients with muscle-invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: A randomized, double-blind, placebo-controlled, phase 3 trial (PROOF 302). (2022) (0)
1652 SURVIVAL OUTCOMES OF PATIENTS WITH GROSSLY POSITIVE NODES AT RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER (2010) (0)
Editorial (2004) (0)
MOLECULAR SUBTYPES OF MUSCLE INVASIVE BLADDER CANCER ARE RELATED TO BENEFIT FROM NEOADJUVANT CHEMOTHERAPY: DEVELOPMENT OF A SINGLE SAMPLE PATIENT ASSAY: MP34‐01 (2017) (0)
Primary bladder sparing therapy (2008) (0)
1031 FACTORS AFFECTING THE ADEQUACY OF LYMPH NODE YIELD IN EXTENDED PELVIC LYMPH NODE DISSECTION FOR UROTHELIAL BLADDER CANCER (2010) (0)
Risk Stratification of Nonmuscle Invasive Bladder Cancer and Innovative Approaches to Management of Ta Low-Grade Tumors. (2022) (0)
The preclinical activity of lenalidomide in urothelial carcinoma (UC). (2012) (0)
MP09-17 WEIGHTED GLEASON GRADE GROUP (WGGG): A NEW PROSTATE CANCER BIOPSY REPORTING SYSTEM WITH PROGNOSTIC POTENTIAL (2019) (0)
Optimizing a risk stratification for local-regional failure after radical cystectomy using the SWOG 8710 cohort. (2014) (0)
In Memory of Dr. John P. Stein (1962-2008) (2008) (0)
Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review. (2023) (0)
Treatment of regionally advanced and metastatic bladder cancer (2008) (0)
Editorial Concerning “Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy” (2017) (0)
MP65-04 TRANSURETHRAL BIOPSY OF THE PROSTATIC URETHRA PREDICTS THE FINAL APICAL MARGIN STATUS AT RADICAL CYSTOPROSTATECTOMY (2014) (0)
323 INTERNATIONAL VALIDATION OF THE PROGNOSTIC VALUE OF LYMPHOVASCULAR INVASION IN RADICAL CYSTECTOMY PATIENTS (2010) (0)
785. Synergism of Combined Radiation and Suicide Gene Therapy Using a Chimeric Adenovirus Vector for Bladder Cancer (2004) (0)
Neural network analysis of tumor and germline profiling to predict survival of muscle-invasive bladder cancer following radical cystectomy: An analysis of the Cancer Genome Atlas (TCGA). (2023) (0)
1594 OUTCOME OF UROTHELIAL BLADDER CANCER WITH HISTOLOGIC VARIANTS AFTER RADICAL CYSTECTOMY (2012) (0)
PD09-02 ANTI-ADENOVIRAL ANTIBODY LEVELS PREDICT NADOFARAGENE FIRADENOVEC RESPONSE IN BCG-UNRESPONSIVE NMIBC: RESULTS FROM A PHASE 3 TRIAL (2021) (0)
Testis cancer--progress in risk assessment for occult retroperitoneal lymph node metastases. (1996) (0)
PROGNOSTIC VALUE OF LYMPH NODE DENSITY IN A MULTI-CENTER, INTERNATIONAL COHORT OF PATIENTS WITH NODE POSITIVE UROTHELIAL CARCINOMA OF THE BLADDER (2009) (0)
ALTERATION OF TRANSFORMING GROWTH FACTOR-beta RECEPTOR TYPE I GENE IN HUMAN TRANSITIONAL CELL CARCINOMA OF THE BLADDER (1999) (0)
1988 PREOPERATIVE SERUM INTERLEUKIN-6 SOLUBLE RECEPTOR PREDICTS LYMPH NODE METASTASIS AND CANCER SPECIFIC SURVIVAL IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER UNDERGOING RADICAL CYSTECTOMY AND EXTENDED LYMPH NODE DISSECTION (2011) (0)
V1057: The Feasibility of Laparoscopic Bladder Augmentation with an Off-The-Shelf Biological Matrix in a Porcine Model (2007) (0)
Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder. (2005) (0)
Drug instillation in the management of urinary tract urothelial carcinoma (2022) (0)
Editorial comment. (2010) (0)
1628 RISK STRATIFICATION FOR LOCAL-REGIONAL FAILURE AFTER CYSTECTOMY (2013) (0)
131Development and internal validation of a nomogram predicting 2,5 and 8-year bladder cancer-specific survival (BCA-NED) after radical cystectomy (2005) (0)
Faculty Opinions recommendation of Bladder cancer detection with CT urography in an Academic Medical Center. (2008) (0)
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434 – 5 (2019) (0)
542 IMPROVED PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED BLADDER CANCER USING A PANEL OF FOUR CELL CYCLE REGULATORS (2009) (0)
Author reply (0)
1259: Prognostic Significance of Deep Muscular Invasion and Extravesical Extension in Pathological Staging of Bladder Cancer after Radical Cystectomy (2006) (0)
IMPROVED PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED BLADDER CANCER USING A PANEL OF FOUR CELL CYCLE REGULATORS (2009) (0)
132A multi-institutional pre-operative prognostic model to predict the risk of locally advanced pathologic stage (PT3+) and of lymph node metastases (PN+) at radical cystectomy: Development and internal validation (2005) (0)
945. Combination Treatment of Adenovirus Mediated HSV-Thymidine Kinase Suicide Gene Therapy and Docetaxel in Bladder Cancer (2006) (0)
Urinary tract reconstruction (2008) (0)
Proteogenomic characterization of muscle invasive bladder cancer identifies mechanisms of resistance and potential targets for therapy (2022) (0)
Editorial comment. (2010) (0)
376 Urine detection of survivin is a powerful marker for the non-invasive diagnosis of bladder cancer (2004) (0)
Influence of facility (Fac) annual caseload (AC) on survival of patients (pts) with respectable urothelial carcinoma (UC) of the bladder. (2018) (0)
A SYSTEMATIC ANALYSIS OF THE PROGNOSTIC ABILITY OF VARIOUS NODAL CODING SCHEMES IN BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY (2008) (0)
Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy? (2022) (0)
MP63-09 GENOMIC PROFILING OF UROTHELIAL CARCINOMA IN SITU OF BLADDER (2023) (0)
322 CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH PT4 UROTHELIAL CARCINOMA AT RADICAL CYSTECTOMY: A RETROSPECTIVE INTERNATIONAL STUDY OF 583 PATIENTS (2010) (0)
Abstract 2998: Targeting resistance mechanisms in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model (2021) (0)
273: Timing of Recurrence and Outcomes Following Induction BCG for High Risk TA, T1 Bladder Cancer - A Southwest Oncology Group Trial (2004) (0)
Phase 1 clinical trial to evaluate the use of a tissue engineered neo-urinary conduit using adipose derived smooth muscle cells after radical cystectomy (2019) (0)
Considerations in the Use of Neoadjuvant and Adjunctive Systemic Chemotherapy in Treatment of Invasive Bladder Cancer by Cystectomy (2001) (0)
Abstract 4801: Stromal-mediated collagen I signal in promoting bladder cancer progression (2014) (0)
The Combination of Multiple Cell Cycle Regulators Improves Prognosis in Patients with Pathologic Organ-Confined Bladder Cancer: A Multicenter External Validation Study (2010) (0)
279: Urodynamic Analysis of the Orthotopic Neobladder: A Comparison of the Hemi-Kock and Studer Ileal Bladder Substitute (2005) (0)
Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project (2016) (0)
1906 POSITIVE SURGICAL MARGINS CONTRIBUTE TO DELAYED FAILURES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER (2012) (0)
MULTI-INSTITUTIONAL EVALUATION OF THE PREDICTIVE VALUE OF P53 IMMUNOHISTOCHEMICAL STAINING IN PATIENTS WITH PT1-2 N0 DISEASE AT RADICAL CYSTECTOMY (2008) (0)
ASSESSEMENT OF THE MINIMUM NUMBER OF LYMPH NODES NEEDED AT RADICAL CYSTECTOMY IN BLADDER CANCER PATIENTS (2008) (0)
Seminar article Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer (2008) (0)
Neutrophil-to-lymphocyte ratio as a prognostic biomarker in bladder cancer: A REMARK-guided secondary analysis of SWOG 8710. (2016) (0)
1847 USE OF PERIOPERATIVE CHEMOTHERAPY IN PATIENTS TREATED WITH RADICAL CYSTECTOMY AND EXTENDED LYMPH NODE DISSECTION FOR UROTHELIAL CARCINOMA OF THE BLADDER AND THE EFFECT IN DOWNSTAGING AND SURVIVAL (2011) (0)
BCM PDX Portal: An Intuitive Web-based Tool for Patient-Derived Xenograft Collection Management, as well as Visual Integration of Clinical and Omics Data (2023) (0)
MP26-15 MOLECULAR SUBTYPING REVEALS LUMINAL BLADDER TUMORS HAVE LOWER RATES OF PATHOLOGICAL UPSTAGING AT RADICAL CYSTECTOMY (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Seth Paul Lerner?

Seth Paul Lerner is affiliated with the following schools:

Université de Montréal
University of Southern California
Baylor College of Medicine

Seth Paul Lerner's Academic­Influence.com Rankings

Seth Paul Lerner's Degrees

Why Is Seth Paul Lerner Influential?

Seth Paul Lerner's Published Works

Published Works

What Schools Are Affiliated With Seth Paul Lerner?

Seth Paul Lerner's AcademicInfluence.com Rankings